Table 2. Pathological response in primary tumors based on criteria proposed by the MD Anderson Cancer Center.

Pathological response (grade)	S-1/cisplatin arm				Paclitaxel/cisplatin arm
	Cohort 1 (n = 41)		Cohort 2 (n = 23)		Cohort 1 (n = 42)		Cohort 2 (n = 23)
	No.	%	No.	%	No.	%	No.	%
I	6	15	3	13	4	10	1	4
IIa	15	37	8	35	19	45	9	39
IIb	11	27	9	39	12	30	11	48
III	4	10	1	4	0	0	0	0
IV	2	5	2	9	2	5	2	9
Unknown	0	0	0	0	0	0	0	0
Unresected	3	7	–	–	5	12	–	–
IIb–IV	17/41	41%	12/23	52%	14/42	33%	13/23	57%